 |
 |
HK J Paediatr (New Series)
Vol 8. No. 3,
2003
|
|
HK J Paediatr (New Series) 2003;8:170-183
Special Article
Current Status of Acute Lymphoblastic Leukaemia in Children
GCF Chan, CH Pui Children's Centre of Cancer and Blood Diseases, Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Hong Kong, China GCF Chan ( 陳志峰 )MD St. Jude Children's Research Hospital and the University of Tennessee Health Science Center, Memphis, Tennessee, USA CH Pui ( 裴正康 )MD Correspondence to: Dr GCF Chan Received October 2, 2002 Supported in part by grant CA-21765 from the National Institute of Health, by a Center of Excellence grant from the State of Tennessee, and by the American Lebanese Syrian Associated Charities (ALSAC). CH Pui is an American Cancer Society-FM Kirby Clinical Research Professor.
Abstract Acute lymphoblastic leukaemia (ALL) is the commonest form of childhood malignancy with an estimated annual incidence of 40 to 50 new cases (<15 years) in Hong Kong. The cure rate for ALL in children has improved drastically over the past 2 decades and is approaching 70% currently. Well-designed collaborative clinical trials had contributed greatly to this success in treatment outcome. The advances in new technology especially in the field of molecular biology also help to revolutionise the process of risk assessment, treatment stratification and disease monitoring. In addition to the advances in treatment, progresses had also been made in the understanding of leukaemogenesis and its associated risk factors, individual susceptibility and prognosis assessment. But while there are more and more childhood ALL children being cured, long-term therapy-related complications starts to emerge and becomes a new challenge. This review article will mainly focus on the recent advances in the areas of leukaemogenesis, prognostic assessment, current treatment design and late effect of ALL management. Keyword : Childhood acute lymphoblastic leukaemia Abstract in Chinese
|
|
 |